{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:01:57Z","timestamp":1790935317867,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    There is a paucity of data in frail patients with multiple myeloma (MM) receiving bispecific antibodies (bsAbs). In LINKER-MM1 (NCT03761108), linvoseltamab (human BCMA\u00d7CD3 bsAb) demonstrated high response rates and a generally manageable safety profile in relapsed\/refractory (RR)MM. This LINKER-MM1\n                    <jats:italic>post hoc<\/jats:italic>\n                    analysis evaluated outcomes of linvoseltamab 200\u2009mg in patients categorized for frailty using the International Myeloma Working Group Frailty Proxy (IMWG-FP), Simplified Frailty Score (SFS), and patient-reported frailty phenotype (PRFP). As of July 23, 2024, 117 patients received linvoseltamab (median follow-up: 21.3 months). The percentage of frail patients varied by measure: IMWG-FP, 27.4%; SFS, 26.5%; and PRFP, 20.5% (8\/4 patients were excluded due to missing IMWG-FP\/PRFP scores, respectively). Objective response rates in non-frail and frail groups, respectively, were: IMWG-FP, 72.7% and 65.6%; SFS, 69.8% and 74.2%; PRFP, 73.0% and 62.5%. Incidence of Grade 3\/4 treatment-emergent adverse events was consistent across non-frail and frail groups (IMWG-FP: 72.7% and 75.0%; SFS%: 73.3% and 74.2; PRFP: 74.2% and 70.8, respectively). Clinical outcomes were consistent in non-frail and frail groups, indicating a favorable risk\u2013benefit profile for linvoseltamab in the frail patients with RRMM from LINKER-MM1. Continued evaluation of linvoseltamab in frail patients with RRMM in clinical trials and real-world settings is warranted.\n                  <\/jats:p>","DOI":"10.1038\/s41408-026-01572-1","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:14:12Z","timestamp":1784981652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Linvoseltamab outcomes by frailty status in patients with relapsed\/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Bumma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Inocencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Akunna","family":"Otele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-2909","authenticated-orcid":false,"given":"Megan","family":"Seraphin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito","family":"Roccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2897-9810","authenticated-orcid":false,"given":"Glenn S.","family":"Kroog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1479-7626","authenticated-orcid":false,"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"1572_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/hematolrep15010015","volume":"15","author":"HL Miller","year":"2023","unstructured":"Miller HL, Sharpley FA. Frail multiple myeloma patients deserve more than just a score. Hematol Rep. 2023;15:151\u20136.","journal-title":"Hematol Rep"},{"key":"1572_CR2","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:2702\u201312.","journal-title":"J Clin Oncol"},{"key":"1572_CR3","unstructured":"Surveillance Epidemiology and End Results (SEER) Program. Cancer Stat Facts: Myeloma. 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"1572_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/cancers17060944","volume":"17","author":"A Aureli","year":"2025","unstructured":"Aureli A, Marziani B, Sconocchia T, Pasqualone G, Franceschini L, Spagnoli GC, et al. Challenges in multiple myeloma therapy in older and frail patients. Cancers (Basel). 2025;17:944.","journal-title":"Cancers (Basel)"},{"key":"1572_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","volume":"29","author":"S Zweegman","year":"2017","unstructured":"Zweegman S, Engelhardt M, Larocca A. Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol. 2017;29:315\u201321.","journal-title":"Curr Opin Oncol"},{"key":"1572_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/jgs.15715","volume":"67","author":"TM Wildes","year":"2019","unstructured":"Wildes TM, Tuchman SA, Klepin HD, Mikhael J, Trinkaus K, Stockerl-Goldstein K, et al. Geriatric assessment in older adults with multiple myeloma. J Am Geriatr Soc. 2019;67:987\u201391.","journal-title":"J Am Geriatr Soc"},{"key":"1572_CR7","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.3390\/cancers15102693","volume":"15","author":"A Larocca","year":"2023","unstructured":"Larocca A, Cani L, Bertuglia G, Bruno B, Bringhen S. New strategies for the treatment of older myeloma patients. Cancers (Basel). 2023;15:2693.","journal-title":"Cancers (Basel)"},{"key":"1572_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00779-2","volume":"13","author":"H Mian","year":"2023","unstructured":"Mian H, McCurdy A, Giri S, Grant S, Rochwerg B, Winks E, et al. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review. Blood Cancer J. 2023;13:6.","journal-title":"Blood Cancer J"},{"key":"1572_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/10428194.2024.2419375","volume":"66","author":"MJ Pianko","year":"2025","unstructured":"Pianko MJ, Mian HS, Schoenbeck KL, Wildes TM. Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice. Leuk Lymphoma. 2025;66:190\u2013203.","journal-title":"Leuk Lymphoma"},{"key":"1572_CR10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/bloodadvances.2024014624","volume":"9","author":"N Abdallah","year":"2025","unstructured":"Abdallah N, Dizona P, Kumar A, LaPlant B, Menser T, Schaeferle G, et al. Cumulative deficits frailty index and relationship status predict survival in multiple myeloma. Blood Adv. 2025;9:1137\u201346.","journal-title":"Blood Adv"},{"key":"1572_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101681","volume":"15","author":"MN Murugappan","year":"2024","unstructured":"Murugappan MN, King-Kallimanis BL, Bhatnagar V, Kanapuru B, Farley JF, Seifert RD, et al. Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: a comparison between two approaches to measuring frailty. J Geriatr Oncol. 2024;15:101681.","journal-title":"J Geriatr Oncol"},{"key":"1572_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.14283\/jfa.2019.25","volume":"8","author":"H Mian","year":"2019","unstructured":"Mian H, Brouwers M, Kouroukis CT, Wildes TM. Comparison of frailty scores in newly diagnosed patients with multiple myeloma: a review. J Frailty Aging. 2019;8:215\u201321.","journal-title":"J Frailty Aging"},{"key":"1572_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2024.104265","volume":"54","author":"X Zhou","year":"2025","unstructured":"Zhou X, Kortuem KM, Rasche L, Einsele H. Bispecific antibody and chimeric antigen receptor (CAR) modified T-cell in the treatment of multiple myeloma: where do we stand today? Presse Med. 2025;54:104265.","journal-title":"Presse Med"},{"key":"1572_CR14","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068\u201374.","journal-title":"Blood"},{"key":"1572_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34:224\u201333.","journal-title":"Leukemia"},{"key":"1572_CR16","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1182\/blood.V126.23.4239.4239","volume":"126","author":"T Facon","year":"2015","unstructured":"Facon T, Hulin C, Dimopoulos MA, Belch A, Meuleman N, Mohty M, et al. A frailty scale predicts outcomes of patients with newly diagnosed multiple myeloma who are ineligible for transplant treated with continuous lenalidomide plus low-dose dexamethasone on the first trial. Blood. 2015;126:4239.","journal-title":"Blood"},{"key":"1572_CR17","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1007\/s11136-023-03390-5","volume":"32","author":"MN Murugappan","year":"2023","unstructured":"Murugappan MN, King-Kallimanis BL, Bhatnagar V, Kanapuru B, Farley JF, Seifert RD, et al. Measuring frailty using patient-reported outcomes (PRO) data: a feasibility study in patients with multiple myeloma. Qual Life Res. 2023;32:2281\u201392.","journal-title":"Qual Life Res"},{"key":"1572_CR18","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","volume":"41","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk NWCJ, Moreau P, Garfall AL, Bhutani M, Oriol A, Nooka AK, et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8011.","journal-title":"J Clin Oncol"},{"key":"1572_CR19","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"1572_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"1572_CR21","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/blood-2024-200877","volume":"144","author":"H Mian","year":"2024","unstructured":"Mian H, Tan CR, Asoori S, Popat R, Abdallah N, Chhabra S, et al. Outcomes of frailty subgroups treated with teclistamab in the real-world: an International Myeloma Foundation study database analysis (Letter). Blood. 2024;144:704.","journal-title":"Blood"},{"key":"1572_CR22","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/bloodadvances.2025015973","volume":"9","author":"B Adegbite","year":"2025","unstructured":"Adegbite B, Tan CR, Shekarkhand T, Firestone RS, Jurgens EM, Miller K, et al. Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed\/refractory multiple myeloma. Blood Adv. 2025;9:4016\u201322.","journal-title":"Blood Adv"},{"key":"1572_CR23","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","volume":"5","author":"DJ DiLillo","year":"2021","unstructured":"DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, et al. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021;5:1291\u2013304.","journal-title":"Blood Adv"},{"key":"1572_CR24","unstructured":"European Medicines Agency. Lynozyfic\u2122 (linvoseltamab) Summary of Product Characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynozyfic."},{"key":"1572_CR25","unstructured":"US Food and Drug Administration. Lynozyfic\u2122 (linvoseltamab) Prescribing Information. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761400s000lbl.pdf."},{"key":"1572_CR26","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.clml.2025.11.004","volume":"26","author":"HC Lee","year":"2026","unstructured":"Lee HC, Zonder JA, Dhodapkar MV, Jagannath S, Hoffman JE, Suvannasankha A, et al. Linvoseltamab in patients with relapsed\/refractory multiple myeloma in the LINKER-MM1 study: longer follow-up and subgroup analyses. Clin Lymphoma Myeloma Leuk. 2026;26:e201\u201312.e8.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1572_CR27","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"1572_CR28","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1572_CR29","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146\u201357.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1572_CR30","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"1572_CR31","unstructured":"Referenced with permission from the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma V.5.2026 \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed July 17, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"1572_CR32","doi-asserted-by":"publisher","first-page":"S406","DOI":"10.1016\/j.htct.2023.09.767","volume":"45","author":"N Raje","year":"2023","unstructured":"Raje N, Leleu X, Lesokhin A, Mohty M, Nooka A, Leip E, et al. Efficacy and safety of elranatamab by age and frailty in patients with relapsed\/refractory multiple myeloma: a subgroup analysis from MagnetisMM-3. Hematol Transfus Cell Ther. 2023;45:S406\u20137.","journal-title":"Hematol Transfus Cell Ther"},{"key":"1572_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejim.2019.07.031","volume":"68","author":"M Pouzoullic","year":"2019","unstructured":"Pouzoullic M, Schott A-M, S\u00e1nchez-Rodr\u00edguez D, Bataille R, Annweiler C. The international St-aging system as a prognostic marker in general senior population: findings from the EPIDOS cohort study. Eur J Intern Med. 2019;68:51\u20134.","journal-title":"Eur J Intern Med"},{"key":"1572_CR34","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1182\/blood.V124.21.4740.4740","volume":"124","author":"A Larocca","year":"2014","unstructured":"Larocca A, Bringhen S, Hajek R, Petrucci MT, Offidani M, Mina R, et al. The combination of frailty and ISS scores identifies a simple prognostic index for overall survival in elderly patients treated with novel agents-based induction therapy. Blood. 2014;124:4740.","journal-title":"Blood"},{"key":"1572_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70268","volume":"9","author":"K Groen","year":"2025","unstructured":"Groen K, Smits F, Nasserinejad K, Levin MD, Regelink JC, Timmers GJ, et al. Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome. Hemasphere. 2025;9:e70268.","journal-title":"Hemasphere"},{"key":"1572_CR36","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1182\/blood-2023-188672","volume":"142","author":"G Cook","year":"2023","unstructured":"Cook G, Pawlyn C, Royle K-L, Senior ER, Everritt D, Bird J, et al. Dynamic frailty assessment in transplant non-eligible newly diagnosed myeloma patients: initial data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): a frailty-adjusted therapy study. Blood. 2023;142:4748.","journal-title":"Blood"},{"key":"1572_CR37","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1182\/blood-2024-208861","volume":"144","author":"GR Mohyuddin","year":"2024","unstructured":"Mohyuddin GR, Godara A, McClune B, Fortuna GG, Sweiss K, Sanchez M, et al. ULTRA FRAIL-MM clinical trial: go-slow approach incorporating isatuximab, lenalidomide and dexamethasone for ultra-frail newly diagnosed myeloma. Blood. 2024;144:6916.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01572-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:47:43Z","timestamp":1790934463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01572-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01572-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hira Mian: Honoraria\/consultancy\n                      : Amgen, Bristol Myers Squibb, Forus, Janssen, Pfizer, Sanofi, Takeda.\n                      Research funding\n                      : Janssen, Pfizer.\n                      Naresh Bumma: Consulting or advisory role\n                      : Janssen, Sanofi.\n                      Speakers\u2019 bureau\n                      : Sanofi.\n                      Joshua Richter: Consulting or advisory role\n                      : AbbVie, Adaptive Biotechnologies, Antengene, Bristol Myers Squibb\/Celgene, Genentech, Janssen, Karyopharm Therapeutics, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Takeda.\n                      Speakers\u2019 bureau\n                      : Adaptive Biotechnologies, Bristol Myers Squibb, Celgene, Janssen, Sanofi.\n                      Travel, accommodations, expenses\n                      : Regeneron Pharmaceuticals, Inc.\n                      Mina Awad, C. Akunna Otele, Timothy J. Inocencio, Tito Roccia, Megan Seraphin, Glenn S. Kroog: Employment\n                      : Regeneron Pharmaceuticals, Inc.\n                      Stock and other ownership interests\n                      : Regeneron Pharmaceuticals, Inc.\n                      Timothy J. Inocencio: Additional stock holdings\n                      : AbbVie and Eli Lilly & Co.\n                      Tanya M. Wildes: Honoraria\/consultancy\n                      : Pfizer, Sanofi.\n                      Research funding\n                      : Janssen.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"170"}}